A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints

Pharmaceutical Statistics

Volumn 11, Issue 2, 2012, Pages 118-128

  Sugimoto, Tomoyuki ^a   Sozu, Takashi ^b   Hamasaki, Toshimitsu ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

correlated endpoints; intersection union test; multivariate normal; power; superiority; two arm design

Indexed keywords

ARTICLE; CALCULATION; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; DRUG DESIGN; INFORMATION PROCESSING; PROCEDURES; SAMPLE SIZE; STUDY DESIGN;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG DESIGN; ENDPOINT DETERMINATION; HUMANS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84858424146     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.505     Document Type: Article

References (17)

1. Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W,. Challenge of mulitiple co-primary endpoints: a new approach. Statistics in Medicine 2007; 26: 1181-1192. DOI: 10.1002/sim.2604. (Pubitemid 46380835)
2. Eaton ML, Muirhead RJ,. On multiple endpoints testing problem. Journal of Statistical Planning & Inference 2007; 137: 3416-3429. DOI: 10.1016/j.jspi.2007.03.021.
3. Offen W, Chuang-Stein C, Dmitrienko A, Littman G, Maca J, Meyerson L, Muirhead R, Stryszak P, Boddy A, Chen K, Copley-Merriman K, Dere W, Givens S, Hall D, Henry D, Jackson JD, Krishen A, Liu T, Ryder S, San-koh AJ, Wang J, Yeh CH,. Multiple co-primary endpoints: medical and statistical solutions. Drug Information Journal 2007; 41: 31-46.
4. Hung HMJ, Wang SJ,. Some controversial multiple testing problems in regulatory applications. Journal of Biopharmaceutical Statistics 2009; 19: 1-11. DOI: 10.1080/10543400802541693.
5. Xiong C, Yu K, Gao F, Yan Y, Zhang Z,. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clinical Trials 2005; 2: 387-393. DOI: 10.1191/1740774505cn112oa. (Pubitemid 41586023)
6. Sozu T, Kanou T, Hamada C, Yoshimura I,. Power and sample size cal-culations in clinical trials with multiple primary variables. Japanese Journal of Biometrics 2006; 27: 83-96.
7. Song JM,. Sample size for simultaneous testing of rate differences in non-inferiority trials with multiple endpoints. Computational Statistics & Data Analysis 2009; 53: 1201-1207. DOI: 10.1016/j.csda.2008.10.028.
8. Sozu T, Sugimoto T, Hamasaki T,. Sample size determination in clinical trials with multiple co-primary binary endpoints. Statistics in Medicine 2010; 29: 2169-2179. DOI: 10.1002/sim.3972.
9. Kordzakhia G, Siddiqui O, Huque MF,. Method of balanced adjustment in testing co-primary endpoints. Statistics in Medicine 2010; 29: 2055-2066. DOI: 10.1002/sim.3950.
10. Sozu T, Sugimoto T, Hamasaki T,. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. Journal of Biopharmaceutical Statistics 2011; 21: 1-19. DOI: 10.1080/10543406.2011.551329.
11. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2005. ISBN 3-900051-07-0, URL.
12. SAS Institute Inc. SAS Online Doc 9.1.3. SAS Institute, Inc.: Cary, NC, 2006.
13. Miwa A, Hayter J, Kuriki S,. The evaluation of general non-centred orthant probabilities. Journal of the Royal Statistical Society Series B 2003; 65: 223-234. DOI: 10.1111/1467-9868.00382. (Pubitemid 37155346)
14. Genz A,. Numerical computation of multivariate normal probabilities. Journal of Computational and Graphical Statistics 1992; 1: 141-150.
15. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT,. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
16. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholmf AL, Jansson-Blixt C, Haglund A,. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. The Lancet 2006; 367: 1057-1065. DOI: 10.1016/S0140-6736(06)68350-5.
17. Committee for Medicinal Products for Human Use (CHMP). Guideline on Medicinal Products for the Treatment Alzheimer's Disease and Other Dementias, (CPMP/EWP/553/95 Rev.1). EMEA: London, 2008.